Jill Desimone Sells Praxis Precision Medicines Shares

Jill Desimone, a key insider at Praxis Precision Medicines, Inc. (NasdaqGS: PRAX), sold 11,600 shares of the company on June 24, 2026. The shares were sold at an average price of $311.32, bringing the total transaction to approximately $3.61 million. This sale was part of a planned trading program.

Other Institutional Activity in Praxis Precision Medicines

Institutional investors have shown varied interest in Praxis Precision Medicines. Janus Henderson Group PLC increased its holdings by 218,777 shares, bringing its total to 3,458,863 shares valued at about $1.11 billion, marking a 6.8% increase. Orbis Allan Gray Ltd made a significant move, adding 1,217,318 shares, a 97% increase, to hold 2,472,480 shares worth $796.6 million. BlackRock, Inc. also boosted its position by 246,429 shares, a rise of 11.9%, to hold 2,324,929 shares valued at $749.1 million. FMR LLC increased its stake by 802,268 shares, a 59% increase, totaling 2,160,943 shares worth approximately $696.2 million. Meanwhile, Perceptive Advisors LLC added 40,000 shares, a modest 2% increase, ending with 2,035,986 shares valued at $656.0 million.

Praxis Precision Medicines, Inc. Stock Down 4.9%

On Saturday, shares of Praxis Precision Medicines (NasdaqGS: PRAX) were trading around $327.79. The company has a market capitalization of approximately $9.14 billion. Despite currently not being profitable, with a forward P/E of -33.41, the stock shows significant volatility with a beta of 2.749. Over the past year, the stock has ranged from a low of $37.19 to a high of $366.52. It has a 50-day moving average of $314.76 and a 200-day moving average of $252.07. The company's financial health is strong, with a current ratio of 15.88 and a quick ratio of 15.66, along with a low debt-to-equity ratio of 0.10.

Insider Buying and Selling at Praxis Precision Medicines, Inc.

On June 24, 2026, Jill Desimone sold 11,600 shares at an average price of $311.32 under a planned sale. Earlier, on the same day, she also bought 11,600 shares at $71.20 each. On June 10, 2026, Dean Mitchell purchased 1,371 shares, and both Jill Desimone and Stuart Arbuckle acquired 648 shares each; these transactions were not part of a planned program.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Praxis Precision Medicines. On June 18, 2026, RBC Capital initiated coverage with a 'buy' rating and a price target of $449. Oppenheimer, Truist Securities, and Deutsche Bank maintained their 'buy' ratings with price targets of $650, $616, and $374, respectively, on June 2, 2026. Wedbush, however, maintained a 'sell' rating with a target of $162. The consensus among 18 analysts is a 'strong buy' with an average price target of $617.67.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing therapies for central nervous system disorders. The company uses its Cerebrum and Solidus platforms to develop precision therapies, including small molecule and antisense oligonucleotide approaches. Key products in its pipeline address conditions like essential tremor and various epileptic encephalopathies. Founded in 2015, Praxis is led by CEO Mr. Marcio Silva De'Souza and employs around 168 people.

Bottom Line

Jill Desimone's recent sale of Praxis Precision Medicines shares is part of a planned transaction. The company's stock remains volatile but has seen significant interest from institutional investors. Analysts continue to have a positive outlook, with a consensus rating of 'strong buy'. As with all 13F filings and insider trades, these reports reflect past actions and may not indicate current positions.